Evidation Health, whose tech helps aggregate health data from wearables and other sources for virtual clinical trials, raises $45M Series D led by B Capital
Context & Ripple Effects
Evidation Health's $45M Series D led by B Capital lands at the start of a funding surge in health-data infrastructure for virtual clinical trials — a thesis the market validated quickly with a reported $153M follow-on at a $1B+ valuation.
The same window saw adjacent plays raise in lockstep: Reify Health's cloud-based trial tools drew a $30M Series B weeks after Evidation's round, HealthVerity's patient-data management platform took a $100M Series D, and Aetion raised $110M for real-world evidence analytics — capital converging on the data layer beneath drug development.
First-order effects
- B Capital converts fund capital into a position in wearable-sourced trial data, while Evidation gains the balance sheet to scale its aggregation pipeline for pharmaceutical sponsors running virtual studies.
Second-order effects
- Rivals are raising parallel war chests — HealthVerity's $100M and Aetion's $110M rounds mean Evidation competes not on whether real-world data reaches trials, but on whose pipeline pharma and insurers contract with first.
Third-order effects
- Reify Health's trajectory — from a $30M Series B in August 2020 to successive $220M rounds at billion-dollar-plus valuations inside two years — suggests this category consolidates around a handful of heavily capitalized data-and-trials platforms rather than staying fragmented.
The trend: Venture capital is consolidating around the real-world health-data layer for virtual clinical trials, with each successive round resetting the price of entry for pharma's data suppliers.